UK – NICE recommends MSD’s Keytruda in combination with chemotherapy for routine treatment of lung cancer

With over 48,000 new cases diagnosed per year, lung cancer is the third most common cancer in the UK.

The National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending MSD’s (known as Merck in the US and Canada) Keytruda (pembrolizumab) when used in combination with carboplatin and paclitaxel as an option for untreated metastatic squamous non-small-cell lung cancer (NSCLC) in adults.

The approval follows a successful monitoring and patient access period through the Cancer Drugs Fund. The decision from NICE marks pembrolizumab as the first immunotherapy to be routinely used in first line settings for metastatic squamous NSCLC, regardless of PD-L1 expression, when combined with chemotherapy…